TScan Therapeutics, Inc.TCRXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 12.20% | 5.2M | — | 2023-06-02 |
| EcoR1 Capital, LLC | 11.70% | 5.0M | — | 2023-06-05 |
| K2 HealthVentures Equity Trust LLC | 9.98% | 5.3M | flat | 2024-11-14 |
| BlackRock, Inc. | 9.50% | 4.6M | flat | 2024-11-08 |
| Adage Capital Partners, L.P. | 8.96% | 3.9M | ▼ -0.39pp | 2024-02-07 |
| Biotechnology Value Fund, L.P. | 7.20% | 3.7M | ▲ +0.40pp | 2024-11-14 |
| Baker Bros. Advisors LP | 6.10% | 2.8M | ▼ -0.40pp | 2024-04-23 |
| Cormorant Global Healthcare Master Fund, LP | 5.15% | 2.5M | — | 2024-04-29 |
| Pitango HealthTech | 4.20% | 2.0M | — | 2024-02-08 |
| GV 2017, L.P. | 1.50% | 641.8K | — | 2024-02-09 |
| Cormorant Asset Management, LP | 0.00% | 89.9K | — | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.